KRO at a glance
KRONOS WORLDWIDE INC (KRO, SEC CIK 1257640) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as May 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), KRONOS WORLDWIDE INC (KRO) reported revenue of $1.9 billion (down 1.5% from FY2024) and a net loss of $110.9 million. Diluted EPS was -$0.96.
- As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding KRONOS WORLDWIDE INC (KRO) shares worth $78.3 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Kramer Kevin B on May 18, 2026 of 3,731 shares at $6.70 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.9B
- −1.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 23 funds
- $78.3M · −1 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes disclosed, risks incorporated by reference to the 2025 Annual Report
- Specific new risk factor: none identified in the 2026 10-Q
- Regulatory, legal, and compliance risks: unchanged from the 2025 Annual Report
- Operational, competitive, and market risks: unchanged from the 2025 Annual Report
- Financial risks: unchanged from the 2025 Annual Report
Management Discussion & Analysis
- Third-quarter revenue $541.1M, up 18% YoY from $456.9M, driven by 14% volume and 5% pricing increases
- Gross margin 24% vs 10% YoY, cost of sales 76% of revenue vs 90%
- TiO₂ segment profit $61.0M vs $15.3M loss YoY, supported by European and North American market-share gains
- Operating cash flow $54.9M through nine months vs $89.6M used YoY; capital expenditures $39.8M
- Outlook: full-year sales, volumes and margins above 2025, with North American demand weakened by economic uncertainty and housing weakness
AI summary of the KRO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 references a press release titled “Kronos Worldwide, Inc.”
- The filing indicates earnings-related information is contained in the referenced press release, covering fiscal year 2026 results
Item EX-99.1: Item EX-99.1
- Q3 net income $34.8M, or $0.30/share, versus a $37.0M loss, signaling substantial earnings recovery
- Net sales $541.1M, up 18%, driven by 14% higher TiO2 sales volumes and 5% pricing gains
Item EX-99.1: Item EX-99.1
- Quarterly dividend maintained at $0.05 per share, signaling continued shareholder distributions
- Payment date December 10, 2026, for shareholders of record November 19, 2026
Item 7.01: Regulation FD Disclosure
- October 28, 2026 press release furnished under Regulation FD
- Exhibit 99.1 contains the substantive company disclosure for investor review
Item 7.01: Regulation FD Disclosure
- Quarterly dividend announcement dated August 5, 2026
- Exhibit 99.2 contains dividend terms and payment details relevant to income-focused shareholders
Item 2.02: Results of Operations and Financial Condition
- Second-quarter 2026 results furnished through Exhibit 99.1 press release dated August 5, 2026
- Financial performance details and investor-relevant metrics contained in the attached earnings release
Item EX-99.1: Item EX-99.1
- Q2 net income $15.2M versus $9.2M loss, reversing to $0.13 EPS from $(0.08)
- Net sales $558.1M, up 13%, driven by 16% higher TiO₂ sales volumes and market-share gains
AI summaries of KRO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for KRO
Don't miss the next KRO filing
- Alerts as it files. A push when KRO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut KRO, by share count.
- Ask anything. An AI agent that reads every KRO filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kramer Kevin B | Buy | May 18, 2026 | 3,731 | $6.70 |
| Kramer Kevin B | Buy | May 18, 2026 | 3,735 | $6.75 |
| Kramer Kevin B | Buy | May 18, 2026 | 335 | $6.76 |
| Kramer Kevin B | Buy | May 18, 2026 | 6,800 | $6.77 |
| MOORE CECIL H JR | A | May 13, 2026 | 5,550 | $7.22 |
| MOORE CECIL H JR | A | May 13, 2026 | 5,550 | $7.22 |
| Kramer Kevin B | A | May 13, 2026 | 5,550 | $7.22 |
| Simmons Michael Shawn | A | May 13, 2026 | 5,550 | $7.22 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.9B | $1.9B |
| Gross Profit | - | $359.3M | $213.0M |
| Operating Income | - | $122.9M | -$36.5M |
| Net Income | - | $86.2M | -$110.9M |
| Gross Margin | - | 19.0% | 11.5% |
| Op. Margin | - | 6.5% | -2.0% |
| Net Margin | - | 4.6% | -6.0% |
| Balance Sheet | |||
| Total Assets | $1.8B | $1.9B | $1.8B |
| Equity | $808.3M | $817.0M | $751.1M |
| ROE | - | 10.6% | -14.8% |
| Per Share | |||
| EPS | - | $0.75 | $-0.96 |
| Cash Flow | |||
| Operating CF | - | $72.5M | $2.5M |
| CapEx | - | $29.5M | $42.9M |
Source: XBRL data in KRONOS WORLDWIDE INC (KRO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate KRO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 23 | $78.3M |
| Q2 2026 | 24 | $63.7M |
| Q1 2026 | 25 | $66.0M |
| Q4 2025 | 24 | $47.6M |
| Q3 2025 | 25 | $63.8M |
| Q2 2025 | 25 | $67.3M |
| Q1 2025 | 23 | $70.0M |
| Q4 2024 | 19 | $80.7M |
- Millennium Management+280.3K (+409%)
- Morgan Stanley+114.8K (+43%)
- Two Sigma Investments+88.6K (+113%)
- JPMorgan Chase & Co+66.8K (+53%)
- BlackRock+53.9K (+3%)
- Dimensional Fund Advisors−248.2K (-9%)
- Citadel Advisors LLC−80.6K (-62%)
- AQR Capital Management−43.8K (-7%)
- Goldman Sachs Group−43.0K (-15%)
- Renaissance Technologies LLC−16.4K (-3%)
- FMR LLC (Fidelity)−16.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 188 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
KRO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 10-K | Mar 9, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 9, 2026 | - | Analysis | - |
| 8-K | Feb 25, 2026 | - | Analysis | - |
| 10-Q | Nov 6, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Aug 6, 2025 | Jun 30, 2025 | - | |
| 10-Q | May 7, 2025 | Mar 31, 2025 | - | |
| 10-K | Mar 6, 2025 | Dec 31, 2024 | - | |
| 10-Q | Nov 6, 2024 | Sep 30, 2024 | - |
Related Health Care companies
- LTBR · LIGHTBRIDGE CorpIndustrial Inorganic Chemicals
- LXU · LSB INDUSTRIES, INC.Industrial Inorganic Chemicals
- LXFR · LUXFER HOLDINGS PLCIndustrial Inorganic Chemicals
- NL · NL INDUSTRIES INCIndustrial Inorganic Chemicals
- TROX · Tronox Holdings plcIndustrial Inorganic Chemicals
- VHI · VALHI INC /DE/Industrial Inorganic Chemicals
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
KRO SEC filings: frequently asked questions
Which institutions hold KRO stock?
As of September 30, 2026, the largest KRONOS WORLDWIDE INC (KRO) holders among the 13F filers tracked by SignalX were Dimensional Fund Advisors ($19.9 million), BlackRock ($13.6 million), Vanguard Capital Management LLC ($7.6 million), BNY Mellon ($6.1 million), AQR Capital Management ($4.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was KRO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), KRONOS WORLDWIDE INC (KRO) reported revenue of $1.9 billion (down 1.5% from FY2024) and a net loss of $110.9 million. Diluted EPS was -$0.96. The figures come from the XBRL data in the 10-K.
What did KRO report in its latest 8-K?
KRONOS WORLDWIDE INC (KRO) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Item 2.02 references a press release titled “Kronos Worldwide, Inc.”.
What are the latest KRO SEC filings?
KRONOS WORLDWIDE INC (KRO) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on May 18, 2026.
What is KRO's SEC CIK number?
KRONOS WORLDWIDE INC (KRO)'s SEC Central Index Key (CIK) is 1257640. EDGAR lists every KRO filing under that number.
Ask anything about KRO
The research agent reads KRO's filings, financials, insider trades and 13F holders, then answers with sources.